Finally, we have suggested that inhibitors of l-glutamine transaminases and especially ω-amidase, either alone or in combination with a GLS1 inhibitor or an l-glutamine transporter may be clinically effective anti-cancer agents. This evidence concerns the gene GLS and cancer.